KDM6B (JMJD3) is an epigenetic modulator that positively regulates the transcription of innate immune and developmental genes involved in the pathogenesis of CMML by modulating the methylation status of H3K4 and H3K27. This evidence concerns the gene KDM6B and chronic myelomonocytic leukemia.